Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24966725 | 1.00 | TSHR (0.37) | TSHRPDK2 | |
| SCHEMBL21070882 | 1.00 | TSHR (0.37) | TSHRPDK2 | |
| SCHEMBL29837023 | 1.00 | TSHR (0.37) | TSHRPDK2 | |
| SCHEMBL21070955 | 0.97 | TSHR (0.39) | TSHRPDK2 | |
| SCHEMBL23085284 | 0.96 | TSHR (0.34) | TSHRPDK2 | |
| SCHEMBL25831188 | 0.92 | TSHR (0.32) | TSHRPDK2 | |
| SCHEMBL22773993 | 0.91 | TSHR (0.41) | TSHRPDK2 | |
| SCHEMBL25829901 | 0.91 | TSHR (0.31) | TSHRPDK2 | |
| SCHEMBL26840791 | 0.89 | TSHR (0.35) | TSHRPDK2 | |
| SCHEMBL21069506 | 0.88 | TSHR (0.44) | TSHRPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024442-A1 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4055019-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024442-A1 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, XIAP, CBL | TSHR 3972/4885PDK2 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.